Therapeutic trial of hematological disorders with intermittent administration of high-dose 1-alpha-hydroxyvitamin D3.
Aplastic anemia and myelodysplastic syndrome were successfully treated with an intermittent administration of high-dose 1 alpha-hydroxy-vitamin D3, an active analogue of 1,25-dihydroxyvitamin D3. This effect was considered to be through the differentiation-inducing and immunomodulatory actions of 1,25-dihydroxyvitamin D3. The only adverse effect was hypercalciuria which was controllable by decreasing the dose.
Imai
Y
Y
Department of Medicine, Kobe University School of Medicine, Japan.
Tsutsumi
M
M
Tsunenari
T
T
Nishikawa
M
M
Matsui
T
T
Natazuka
T
T
Fujita
T
T
D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
D006887:Hydroxycholecalciferols; C008088:alfacalcidol